Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,483
archived clinical trials in
Influenza

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine
A Phase III, Randomized, Multinational Study, Double-blinded for the Immunogenicity and Consistency Evaluation of 3 Hib-MenCY-TT Vaccine Lots and Single-blinded and Controlled for the Evaluation of Safety and Immunogenicity of GSK Biologicals' Haemophilus Influenzae Type b and Neisseria Meningitidis Serogroups C and Y-tetanus Toxoid Conjugate Vaccine Combined (Hib-MenCY-TT) Compared to Monovalent Hib Vaccine in Healthy Infants at 2, 4, 6, and 12 to 15 Months of Age.
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Randwick,
Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine
A Phase III, Randomized, Multinational Study, Double-blinded for the Immunogenicity and Consistency Evaluation of 3 Hib-MenCY-TT Vaccine Lots and Single-blinded and Controlled for the Evaluation of Safety and Immunogenicity of GSK Biologicals' Haemophilus Influenzae Type b and Neisseria Meningitidis Serogroups C and Y-tetanus Toxoid Conjugate Vaccine Combined (Hib-MenCY-TT) Compared to Monovalent Hib Vaccine in Healthy Infants at 2, 4, 6, and 12 to 15 Months of Age.
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Randwick,
Click here to add this to my saved trials
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of Age
Status: Enrolling
Updated:  12/31/1969
US135
mi
from
Hollywood, FL
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of Age
Status: Enrolling
Updated: 12/31/1969
US135
mi
from
Hollywood, FL
Click here to add this to my saved trials
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of Age
Status: Enrolling
Updated:  12/31/1969
Research Site US045
mi
from
Savannah, GA
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of Age
Status: Enrolling
Updated: 12/31/1969
Research Site US045
mi
from
Savannah, GA
Click here to add this to my saved trials
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of Age
Status: Enrolling
Updated:  12/31/1969
Research Site US013
mi
from
Stockbridge, GA
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of Age
Status: Enrolling
Updated: 12/31/1969
Research Site US013
mi
from
Stockbridge, GA
Click here to add this to my saved trials
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of Age
Status: Enrolling
Updated:  12/31/1969
US138
mi
from
Rockville, MD
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of Age
Status: Enrolling
Updated: 12/31/1969
US138
mi
from
Rockville, MD
Click here to add this to my saved trials
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of Age
Status: Enrolling
Updated:  12/31/1969
Research Site US025
mi
from
Norfolk, NE
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of Age
Status: Enrolling
Updated: 12/31/1969
Research Site US025
mi
from
Norfolk, NE
Click here to add this to my saved trials
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of Age
Status: Enrolling
Updated:  12/31/1969
Research Site US018
mi
from
Omaha, NE
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of Age
Status: Enrolling
Updated: 12/31/1969
Research Site US018
mi
from
Omaha, NE
Click here to add this to my saved trials
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of Age
Status: Enrolling
Updated:  12/31/1969
Research Site US078
mi
from
Cary, NC
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of Age
Status: Enrolling
Updated: 12/31/1969
Research Site US078
mi
from
Cary, NC
Click here to add this to my saved trials
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of Age
Status: Enrolling
Updated:  12/31/1969
Research Site US108
mi
from
Raleigh, NC
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of Age
Status: Enrolling
Updated: 12/31/1969
Research Site US108
mi
from
Raleigh, NC
Click here to add this to my saved trials
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of Age
Status: Enrolling
Updated:  12/31/1969
US137
mi
from
Salisbury, NC
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of Age
Status: Enrolling
Updated: 12/31/1969
US137
mi
from
Salisbury, NC
Click here to add this to my saved trials
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of Age
Status: Enrolling
Updated:  12/31/1969
Research Site US132
mi
from
Statesville, NC
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of Age
Status: Enrolling
Updated: 12/31/1969
Research Site US132
mi
from
Statesville, NC
Click here to add this to my saved trials
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of Age
Status: Enrolling
Updated:  12/31/1969
Research Site US071
mi
from
Wilmington, NC
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of Age
Status: Enrolling
Updated: 12/31/1969
Research Site US071
mi
from
Wilmington, NC
Click here to add this to my saved trials
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of Age
Status: Enrolling
Updated:  12/31/1969
Research Site US063
mi
from
Winston-Salem, NC
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of Age
Status: Enrolling
Updated: 12/31/1969
Research Site US063
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of Age
Status: Enrolling
Updated:  12/31/1969
US056
mi
from
Moncks Corner, SC
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of Age
Status: Enrolling
Updated: 12/31/1969
US056
mi
from
Moncks Corner, SC
Click here to add this to my saved trials
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of Age
Status: Enrolling
Updated:  12/31/1969
Research Site US050
mi
from
Dakota Dunes, SD
Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults
Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of Age
Status: Enrolling
Updated: 12/31/1969
Research Site US050
mi
from
Dakota Dunes, SD
Click here to add this to my saved trials
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years
A Trial to Evaluate the Safety & Immunogenicity of Investigational Influenza Vaccine GSK1557484A in Adults 18-64 Yrs of Age
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Huntsville, AL
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years
A Trial to Evaluate the Safety & Immunogenicity of Investigational Influenza Vaccine GSK1557484A in Adults 18-64 Yrs of Age
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Huntsville, AL
Click here to add this to my saved trials
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years
A Trial to Evaluate the Safety & Immunogenicity of Investigational Influenza Vaccine GSK1557484A in Adults 18-64 Yrs of Age
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Anaheim, CA
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years
A Trial to Evaluate the Safety & Immunogenicity of Investigational Influenza Vaccine GSK1557484A in Adults 18-64 Yrs of Age
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Anaheim, CA
Click here to add this to my saved trials
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years
A Trial to Evaluate the Safety & Immunogenicity of Investigational Influenza Vaccine GSK1557484A in Adults 18-64 Yrs of Age
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Miami, FL
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years
A Trial to Evaluate the Safety & Immunogenicity of Investigational Influenza Vaccine GSK1557484A in Adults 18-64 Yrs of Age
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years
A Trial to Evaluate the Safety & Immunogenicity of Investigational Influenza Vaccine GSK1557484A in Adults 18-64 Yrs of Age
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Stockbridge, GA
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years
A Trial to Evaluate the Safety & Immunogenicity of Investigational Influenza Vaccine GSK1557484A in Adults 18-64 Yrs of Age
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Stockbridge, GA
Click here to add this to my saved trials
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years
A Trial to Evaluate the Safety & Immunogenicity of Investigational Influenza Vaccine GSK1557484A in Adults 18-64 Yrs of Age
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Lenexa, KA
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years
A Trial to Evaluate the Safety & Immunogenicity of Investigational Influenza Vaccine GSK1557484A in Adults 18-64 Yrs of Age
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Lenexa, KA
Click here to add this to my saved trials
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years
A Trial to Evaluate the Safety & Immunogenicity of Investigational Influenza Vaccine GSK1557484A in Adults 18-64 Yrs of Age
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Missoula, MT
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years
A Trial to Evaluate the Safety & Immunogenicity of Investigational Influenza Vaccine GSK1557484A in Adults 18-64 Yrs of Age
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Missoula, MT
Click here to add this to my saved trials
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years
A Trial to Evaluate the Safety & Immunogenicity of Investigational Influenza Vaccine GSK1557484A in Adults 18-64 Yrs of Age
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Las Vegas, NV
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years
A Trial to Evaluate the Safety & Immunogenicity of Investigational Influenza Vaccine GSK1557484A in Adults 18-64 Yrs of Age
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years
A Trial to Evaluate the Safety & Immunogenicity of Investigational Influenza Vaccine GSK1557484A in Adults 18-64 Yrs of Age
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Halifax,
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years
A Trial to Evaluate the Safety & Immunogenicity of Investigational Influenza Vaccine GSK1557484A in Adults 18-64 Yrs of Age
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Halifax,
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Birmingham, AL
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Benton, AR
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Benton, AR
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Huntington Beach, CA
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Paramount, CA
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Paramount, CA
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
West Covina, CA
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
West Covina, CA
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Marietta, GA
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Marietta, GA
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Woodstock, GA
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Woodstock, GA
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
DeKalb, IL
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
DeKalb, IL
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Newton, KA
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Newton, KA
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Wichita, KA
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Wichita, KA
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Woburn, MA
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Woburn, MA
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Stevensville, MI
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Stevensville, MI
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Saint Louis, MO
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Henderson, NV
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Henderson, NV
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Cortland, NY
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Cortland, NY
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Syracuse, NY
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Syracuse, NY
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Cary, NC
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Cary, NC
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Raleigh, NC
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Raleigh, NC
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Austintown, OH
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Austintown, OH
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Albany, OR
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Albany, OR
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Erie, PA
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Erie, PA
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Hermitage, PA
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Hermitage, PA
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Charleston, SC
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Austin, TX
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Houston, TX
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Orem, UT
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Orem, UT
Click here to add this to my saved trials
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Provo, UT
Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children
Immunogenicity & Safety Study of GSK Biologicals' Thimerosal-free Trivalent Influenza Vaccine (TIV) Versus a Licensed Comparator in Children
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Provo, UT
Click here to add this to my saved trials